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ABSTRACT
Experiments were performed in a modified microfluidic platform recapitulating 
part of the in vivo tumor microenvironment by co-culturing carcinoma cell aggregates 
embedded in a three-dimensional (3D) collagen scaffold with human umbilical vein 
endothelial cells (HUVECs). HUVECs were seeded in one channel of the device to 
initiate vessel-like structures in vitro prior to introducing the aggregates. The lung 
adenocarcinoma cell line A549 and the bladder carcinoma cell line T24 were tested. 
Dose-response assays of four drugs known to interfere with Epithelial Mesenchymal 
Transition (EMT) signaling pathways were quantified using relative dispersion as 
a metric of EMT progression. The presence of HUVECs in one channel induces cell 
dispersal in A549 which then can be inhibited by each of the four drugs. Complete 
inhibition of T24 aggregate dispersal, however, is not achieved with any single agent, 
although partial inhibition was observed with 10 μM of the Src inhibitor, AZD-0530. 
Almost complete inhibition of T24 dispersal in monoculture was achieved only when 
the four drugs were added in combination, each at 10 μM concentration. Coculture 
of T24 with HUVECs forfeits the almost-complete inhibition. The enhanced dispersal 
observed in the presence of HUVECs is a consequence of secretion of growth factors, 
including HGF and FGF-2, by endothelial cells. This 3D microfluidic co-culture platform 
provides an in vivo-like surrogate for anti-invasive and anti-metastatic drug screening. 
It will be particularly useful for defining combination therapies for aggressive tumors 
such as invasive bladder carcinoma.
INTRODUCTION
The death of most cancer patients is attributed to 
metastasis [1]. Micro-metastasis often remains after 
conventional surgery, radiotherapy and/or chemotherapy, 
and attempts to treat metastatic cancers have been 
generally unsuccessful thus far leading to only slightly 
slowed progression and increased overall survival. Most 
cancers originate from epithelial tissues, and the process 
of epithelial to mesenchymal transition (EMT) confers 
cells with migratory and invasive properties [2, 3]. In this 
process, carcinoma cells lose their cell-cell junctions 
and gain an invasive, fibroblast-like morphology, 
delaminate from the tumor, and intravasate into blood 
and lymph vessels. Following decades of research, EMT 
is believed to be a focal event involved in the progression 
of carcinoma, as well as in generating cancer-initiating 
cells and in inducing drug resistance [4, 5]. A new 
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anti-metastatic strategy based on inhibiting EMT could 
impact survival.
Complex networks orchestrate EMT, including 
activation of a plethora of surface receptors by growth 
factors, cytokines and extracellular matrix (ECM) 
components [3, 6–8]. Some of these pathways cooperate to 
induce EMT with tumor stromal cells, such as endothelial 
cells, fibroblasts, and tumor-associated macrophages 
[9]. Existing in vitro EMT models (e.g., Transwell™ 
technology) are also capable of endothelial–tumor 
co-culture experiments and are achieved by placing 
endothelial cells on the upper surface of the membrane 
in close proximity to a lower layer of tumor cells or 
matrix-containing tumor spheroids to form a three-
dimensional (3D) system. However, this technology 
does not adequately address the topology of the tumor 
components. In addition, it impairs real-time imaging, 
rendering tracking of individual cells difficult. Thus, there 
exists an urgent need to develop more suitable in vitro 3D 
assays that can recapitulate the tumor microenvironment.
Microfluidic assays have been employed in 
various applications to make in vitro assays more 
realistic, replicating angiogenesis, some of the aspects 
of organ function, and tumor-endothelial interactions; 
they have also been used for biopsy studies [10]. By 
integrating complex environmental factors with assays 
and on-chip co-culture, this technique controls the 3D 
microenvironment and enables real-time imaging. Our 
previous work has demonstrated an intermediate drug 
assay model capable of monitoring the inhibition of 
cancer cells migrating away from the primary tumor in 
3D culture [11]. This system integrated tumor aggregates 
in a 3D hydrogel scaffold in close proximity to an 
endothelial monolayer for screening therapeutic EMT 
blocking agents. This previous study demonstrated the 
potential of the microfluidic concept to identify inhibitors 
of lung adenocarcinoma A549 aggregate dispersal, which 
is known to be easily reversible from a mesenchymal to an 
epithelial phenotype.
The current study, in addition to extending the 
analysis on A549 carcinoma aggregates, seeks to identify 
drugs that, in combination, could abrogate dispersal of 
a highly invasive bladder carcinoma cell line. Bladder 
carcinoma, which becomes life-threatening upon 
conversion from a superficial to an invasive phase, has 
yet to truly benefit from the advancements in therapeutic 
interventions, with the exception of the use of attenuated 
Bacillus Calmette-Guérin (BCG) intravesical instillation 
for superficial tumors. Unfortunately, the transition to 
refractory invasive tumors is almost inevitable. Thus, 
here we undertook a microfluidics approach to screen 
for large panels of drug in combination. Employing an 
improved two-gel system, we performed dose-response 
assays of four potential drug candidates using the bladder 
carcinoma T24 cell line [12]. We show that the drugs 
were less effective in inhibiting T24 cells than A549 
cells. Specifically, human umbilical vein endothelial 
cells (HUVECs) induced cell dispersion in A549 cells, 
but this dispersion could be inhibited by each of the four 
drugs. However, inhibiting the spontaneous dispersal of 
T24 aggregates proved more difficult. Without HUVECs, 
higher doses of each drug were required, and only partial 
inhibition could be achieved at 10 μM concentrations of a 
Src inhibitor, AZD-0530. Even when the four drugs were 
used in combination, each at a concentration of 10 μM, 
dispersal was not completely blocked. In the presence 
of HUVECs, drug resistance was further enhanced. 
Combination of the four drugs failed to inhibit T24 
aggregate dispersal either alone at 10 μM concentration 
or in combination. Growth factor tests, ELISA, and 
neutralized antibody blocking experiments revealed 
that the enhanced dispersal observed in the presence of 
HUVECs was due to the secretion of growth factors, 
including HGF and FGF-2, by endothelial cells. The 
addition of AZD-0530 did not affect the activities of HGF 
or FGF-2 in inducing cell dispersal. A previous report 
used integrin-blocking experiments to show that T24 
is sensitive to integrin β1-collagen-induced migration 
for individual cells [13]. However, in the present study, 
dispersal from aggregates was found to be largely integrin 
β1-independent.
RESULTS
A549 and T24 cell lines were selected for this study to 
investigate EMT and tumor progression, since they exhibit a 
reversible EMT phenotype that could potentially be blocked 
to achieve EMT reversal. For this study, a microfluidic 
system (Figure 1(a-c),Supplementary Figure S1) was used, 
similar in design to a previously reported system [11] except 
that it incorporated two different 3D collagen compartments 
between the two media channels. The second gel region was 
added in order to permit the formation of a more uniform 
endothelial monolayer. In particular, we have now allowed 
endothelial cells to form a blood vessel. The carcinoma 
cell aggregates are introduced in the compartment distal to 
the channel in which the endothelial cells had assembled 
to mimic the vascular wall. The endothelial monolayer 
structure exhibited clear cell-cell junctions, as evidenced by 
VE-cadherin staining (Figure 1(d)). Integrity of this HUVEC 
monolayer was also quantified by testing the permeability 
to 70-kDa dextran rhodamine (Figure 1(e)). The significant 
drop in fluorescence intensity at the boundary of the first gel 
(where the HUVEC monolayer resides and highlighted in 
red rectangle) indicated the formation of an intact monolayer 
for the drug diffusive microenvironment. Dispersion was 
quantified and a positive correlation between EMT marker 
expression and a normalized dispersion of aggregates was 
observed (see Figure 2(a), 3(a)).
To test the microfluidic drug screening platform 
for cancer-type specificity, A549 and T24 aggregates 
were formed in non-adhesive, laser-generated microwells 
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and cultured in the devices. Results for the A549 cells 
demonstrated that the aggregates do not disperse when 
cultured in the absence of HUVECs, consistent with 
our previous study [11]. In the presence of HUVECs, 
aggregates did disperse, although each of the drugs—
MK-2206, AZD-0530, A83–01 and CI-1033 (Figure 1(f)) 
—could fully suppress dispersal, each at a particular 
dose (Figure 2(b)-dispersion,Supplementary Figure S2. 
1-cell number) within the range of concentrations tested. 
Thus, we next tested combinations of these same drugs. 
Interestingly, the EGFR inhibitor MK-2206, CI-1033, 
and an AKT inhibitor showed a significant synergistic 
effect, in that the amount of drug required for inhibition of 
dispersion was reduced to one-fifth that required for each 
drug individually. Inhibition of aggregate dispersion was 
reduced from 500 nM to less than 100 nM for each (Figure 
2(c)-dispersion, Supplementary Figure 2(d)-cell number). 
Isobologram for synergistic effects between CI-1033 and 
MK-2206 is shown in Supplementary Figure S2.2.
Compared with A549 cells, the dispersion of 
T24 aggregates alone or in the absence of HUVECs 
could not be suppressed by any of the four drugs; 
albeit, a partial inhibition was observed using the 
Src inhibitor, AZD-0530, at 10 μM (Figure 3(b)-
dispersion,Supplementary Figure  S3-cell number). Only 
when the four drugs were added in combination, each at 
10 μM concentration (Figure 4(a)-morphology (-HUVEC), 
(b)-dispersion (-HUVEC)) was almost complete inhibition 
obtained, which could be considered an additive, rather 
than synergistic effect. The results indicated that, among 
the four drugs tested, AZD-0530 is the most effective in 
preventing spontaneous dispersion of the T24 aggregates. 
In the presence of HUVECs, each drug had some inhibitory 
activity on aggregate dissociation; albeit, individually, they 
were each unable to reduce the dispersion value to less 
than 3 (complete inhibition corresponds to a value of 1). 
Even AZD-0530 was unable to inhibit dispersal when 
aggregates were co-cultured with HUVECs (Figure 3(c)). 
Figure 1: Microfluidic co-culture platform for drug screening. a. Schematic of device design shows the overall layout of the 
media channels and gel regions, where the two regions in the middle are used for introducing collagen gel and the two side channels for 
filling culture medium and growing of endothelial cells. b. Photograph of the PDMS device. c. An enlarged isometric view of the device 
showing the relative locations of co-culturing tumor aggregates and endothelial cells (HUVECs). d. HUVECs monolayer formed after 4 h 
and 36 h, respectively, in the microfluidic channel. Green fluorescence is used for VE-cadherin; blue fluorescence indicates DAPI-stained 
nuclei. e. Concentration profiles of fluorescent dextran from which permeability can be quantified. A jump in fluorescence concentration 
on the right side (circled in red) is due to the presence of the intact endothelial monolayer, thus small molecules can only diffuse through 
the monolayer, resembling drug diffusing out of a blood vessel. f. Drugs used in this study, with the targeting pathways and stage of 
development.
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Figure 2: Screening therapeutic drugs on A549 aggregates over 36 h. a. Staining of EMT markers E-cadherin and vimentin 
in A549 aggregates at 0 h and 36 h. Green fluorescence is used for both E-cadherin (left panels) and for vimentin (right panels); blue 
fluorescence is DAPI-stained nuclei. b. Normalized dispersion measured for three concentrations with four drugs at 12 h and 36 h (MK-
2206: Akt inhibitor; AZD-0530: Src inhibitor; A83–01: TGF-βR inhibitor; CI-1033: EGFR inhibitor), for three different concentrations in 
the presence of HUVEC. c. Normalized dispersion measured over time (12 h and 36 h) for analysis synergistic effects between CI-1033 and 
MK-2206, at four different concentrations (left: dispersion; right: cell number).
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A summary of the AZD-0530 effect in both absence and 
presence of HUVEC is shown in Supplementary Figure 
S3(d)-dispersion, S3(e)-morphology.
It is worthwhile noting that the spontaneous 
dispersion of T24 aggregates alone, without co-culture, is 
about 3, similar to the value observed in co-culture with 
HUVECs when maximally inhibited by individual drugs. 
Even when used in combination, complete inhibition of 
T24 cancer aggregates dispersal could not be achieved 
with a combination of any two drugs (Supplementary 
Figure S4), or when all four drugs were used in 
combination at 10 μM each (Figure 4(a)-morphology 
(+HUVEC), 4(b)-dispersion (+HUVEC)), albeit a slight 
improvement (dispersion reduced to < 2) was observed 
for all four drugs compared to any single drug or any 
combination of two drugs (Supplementary Table S1).
Figure 3: Screening therapeutic drugs on T24 aggregates over 36 h in the presence/absence of HUVECs. a. Staining of 
EMT markers E-cadherin and vimentin in T24 aggregates at 0 h and 36 h. Green fluorescence is used for both E-cadherin (left panels) and 
for vimentin (right panels); blue fluorescence is DAPI-stained nuclei. b. Normalized dispersion of T24 cells with four drugs, in the absence 
of HUVECs, at 12 h and 36 h, for three different concentrations. AZD-0530 is effective at 10,000 nM. c. Normalized dispersion of T24 
cells with four drugs, in the presence of HUVECs, at 12 h and 36 h, for three different concentrations. AZD-0530 is not effective at 10,000 
nM. d. Summary of normalized dispersion between control and AZD-0530 (10 μM), treated group, in the presence/absence of HUVECs at 
36 h. e. Qualitative images of (d).
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It is likely that some factor(s) — other than those 
targeted by the drugs listed — are secreted by HUVECs 
and induce dispersal, bypassing Src signaling. Thus, 
we next investigated a group of EMT-inducing growth 
factors, including TGF-β1, TGF-β3, EGF, FGF-2, 
HGF and PDGF. These factors are possibly secreted by 
endothelial cells to mediate EMT. In the presence of 
AZD-0530, HGF and FGF-2-induced aggregate dispersal 
was reduced to a level comparable with that obtained in 
co-culture with HUVECs, whereas TGF-β3 and EGF 
exhibited less of an effect, plus TGF-β1 and PDGF had 
little effect (Supplementary Figure S5.1). To analyze 
whether endothelial cells might be inducing EMT in T24 
cells through secretion of HGF/FGF-2, we first measured 
HGF/FGF-2 secretion by HUVECs using ELISA. 
Concentrations of FGF-2 in co-culture were found to be 
three times higher than in cultures with aggregates only 
(Figure 5(a)). Similarly, endothelial cell secretion of HGF 
was 5-fold higher in co-culture conditions as compared 
with aggregates alone (Figure 5(b)). The presence of AZD-
0530 did not affect the concentrations of either growth 
factor, and the addition of EGM to the aggregates had 
no significant effect. This suggests that endothelial cells 
produce HGF and FGF-2 in co-culture conditions, even in 
the absence of T24 aggregate co-cultures.
In co-culture with HUVECs, T24 aggregate 
dispersal was reduced to 40% of control when treated 
with the HGF neutralizing antibody (Figure 5(c)). The 
inhibition effect is the same as that achieved by each of the 
individual drugs. Interestingly, in T24 aggregates alone, 
the antibody against HGF had little effect on inhibiting 
dispersal, regardless of the presence or absence of AZD-
0530. A neutralizing antibody against FGF-2 delivered a 
similar degree of inhibition to that observed with anti-HGF 
antibodies. To validate the antibody inhibitory effects, 
a c-Met inhibitor, JNJ-38877605 (Johnson & Johnson), 
Figure 4: Drug combination analysis on T24 cell aggregates. a. Qualitative images showing the effect of drug used in combinations 
of four, in the presence or absence of HUVECs at various doses, 10 μM and 20 μM at 0 h and 36 h. b. Comparison between AZD-0530 (used 
alone at 10 μM) and drugs in combinations of four, in the presence or absence of HUVECs at various doses. Concentrations given are for 
each drug individually (e.g. combined 5 μM means each drug used at a concentration of 5 μM)
Oncotarget7www.impactjournals.com/oncotarget
Figure 5: Analysis of endothelial cell secretion of HGF and FGF-2 in co-culture or by T24 cells alone (AZD-0530 was 
used alone at 10 μM, EGM-2 is the medium control). a. ELISA measurement of FGF-2 concentration. b. ELISA measurement of 
HGF concentration. c. Neutralized antibody blocking experiment (HGF and FGF-2).
Figure 6: Blocking integrin β1 assay in microfluidic device. a. Qualitative image for T24 aggregate dispersion with 20 μg/ml β1 antibody, 
in the absence/presence of HUVECs. b. In the presence of HUVECs, qualitative image for T24 aggregate dispersion with 10 μM AZD-0530.
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and an FGFR inhibitor, TKI-258 (Novartis), were applied 
each at 10 μM. The results are consistent with the antibody 
blocking experiment of anti-HGF and anti-FGF-2, leading 
to dispersal values of approximately 3 (Supplementary 
Figure S5.2).
Finally, we investigated the role of integrin β1 on 
inducing aggregate dispersal via Src signaling. Integrin 
β1 was blocked by a neutralizing antibody in T24 
aggregates in the absence or presence of AZD-0530, both 
in 2D and 3D conditions. T24 aggregate dispersal could 
not be inhibited by blocking integrin β1 in 3D, either 
with aggregates alone or in co-culture conditions that 
induced dispersion (Figure 6(a)). Even in the presence 
of 10 μM AZD-0530, blocking of integrin β1 on T24 co-
cultured with HUVECs could not prevent dispersion from 
aggregates (Figure 6(b)). In contrast, it has previously 
been shown that blocking of integrin β1 in 2D can 
efficiently inhibit the migration of T24 cells [13]; our 
results in 2D were consistent with these previous findings 
(data not shown).
DISCUSSION
Cancer is a systemic disease occurring in a 3D 
microenvironment and involves a complex interaction 
of stromal cells, vascular cells and the tumor, which 
orchestrate a series of cellular events, often leading to 
invasion and metastasis. The heterogeneity of various 
cancer types further complicates these issues, giving rise 
to the altered efficacy of specific compounds under certain 
conditions. In this study, we tested drug responses (alone 
and in combination) on two different cell lines, with a 
special emphasis on invasive bladder cancer.
Cancer patients usually have elevated serum level of 
growth factors, namely, epidermal growth factor (EGF), 
and transforming growth factor-beta (TGF-b). Moreover, 
there are observed over-expression of tyrosine and serine 
threonine kinases, e.g. Src, Akt. The kinase oncogenes 
play essential roles in growth factor signal transduction 
regulation. Dysregulation of them could cause resistance 
to cancer cell death and excessive proliferation, in the 
meantime, initiating and sustaining EMT program, since 
EMT is modulated by similar signaling pathways for 
which these molecules have been generated [14]. Small 
molecule inhibitors against those kinases were developed 
originally as inhibitors of cell proliferation and have been 
effective in pre-clinical/clinical trials; these inhibitors 
were more recently discovered to interfere with EMT, as 
reported in detailed by Chua, et.al in 2012 [14]. Drugs 
inhibiting EGFR and Src have also been shown to affect 
cell motility and invasiveness [15].
By integrating multiple biochemical and biophysical 
factors and multiple cell types, a microfluidic platform 
with individual cancer microenvironmental chambers was 
used to help facilitate an understanding of the crosstalk 
between cancer and stromal cells. Our microfluidic co-
culture with an endothelial cell monolayer and cancer 
aggregates was able to recapitulate some of the cross-
talk that promotes EMT by paracrine interactions 
between these cell types. A subsequent study from our 
laboratory will bring in stromal cells, however this study 
is mandatory to semi-quantitate the behavior of carcinoma 
cells in 3D collagen in the presence of blood vessels. The 
integrated system has the potential to be cost-effective 
and importantly, sensitive with minimum sample usage. 
Robustness and less likelihood of human error have the 
additional benefit of reducing the workload.
Our 3D system also revealed important differences 
between 2D and 3D culture in terms of EMT, and allowed 
for the real-time visualization and quantification of cell 
dissemination from aggregates. The two-gel region 
microfluidic system used in this study was motivated 
by a need to grow an intact endothelial monolayer prior 
to embedding the 3D cancer cell aggregates. We found 
from our previous work that a stabilized, low permeability 
monolayer was key to reproducing the dynamics of 
drug delivery and that it offered a better model for the 
process of drug diffusion across blood/lymph vessel 
walls into the ECM surrounding the tumor [11]. This 
combination of 3D co-culture with drug transport across 
an endothelial monolayer into the matrix surrounding the 
tumor cell aggregate has the potential for drug screening 
in a more physiologically-relevant setting, compared 
to our previous system. Moreover, endothelial derived 
growth factors are also important constituents in the 
tumor microenvironment, and their presence in the 
present experiments further contributes to in vivo fidelity. 
These morphological metrics were supplemented by 
measurements of epithelial (E-cadherin) and mesenchymal 
(vimentin) marker expression to assess EMT progression 
(Figure 2(a)-A549, 3(a)-T24).
In A549 cells, the rapid dissociation of compact 
cancer aggregates by endothelial cells was reversed 
by inhibitors of several receptor tyrosine kinases and 
intracellular kinases (Figure 4). Our data suggest that 
several pathways were activated in A549 cells by 
endothelial-secreted growth factors. We also observed a 
synergistic effect using an EGFR inhibitor (CI-1033) in 
conjunction with an Akt inhibitor (MK-2206). Previous 
studies have suggested that this synergistic effect leads 
to actin cytoskeletal disorganization and, potentially, 
regulation of Rho GTPases [16]. These findings provide 
references for the future direction of drug usage in lung 
adenocarcinoma.
The T24 bladder carcinoma cell line exhibits a 
mesenchymal-like phenotype, with an EMT score of 
0.53 [17] and a more aggressive behavior than lung 
adenocarcinoma A549, which has an EMT score of 0.28, 
indicative of more intermediate epithelial-mesenchymal 
phenotype. In T24 cells, spontaneous dispersal was readily 
observed in 3D collagen gels. This implies that the two 
carcinoma cell lines differ significantly in their ability to 
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respond to a collagen-containing ECM, thus influencing 
their invasive behaviors. Bladder carcinoma cell lines 
share remarkable invasive properties with bladder tumors, 
which, in vivo, lead to the rapid invasion of the bladder 
wall. A critical initial step in the development of these 
approaches is to understand the signaling mechanisms 
that regulate the tendency for invasion. Changes in 
the composition and differentiation status of stromal 
cells accompany the development of malignant cells. 
Angiogenesis is a critical step at the early stages of tumor 
progression, which not only contributes to growth of the 
tumors but, together with other stromal cells, can also 
promote the dissociation of carcinoma cells. Endothelial 
cells are recognized as regulators of cancer progression 
with a synergistic effect adding to the tendency for cancer 
cells to spontaneously invade the surrounding tissues. 
Comprehensive analysis of the secretion protein profiles 
of HUVECs has revealed that multiple paracrine factors 
could play a role in triggering cancer progression [18].
The presence or absence of endothelial cells also 
contributes to the differences of drug efficacy in T24 cells. 
This might explain why some drugs seem to be effective 
in the earlier screening stage, however, fail in later in 
vivo testing. In this experiment, drugs targeting Akt, 
EGFR, or TGFβR suppress HUVEC-induced aggregate 
dispersion from 6–7-fold to ~3-fold, suggesting that 
endothelial cells produce EGF and members of the TGFβ 
family. Interestingly, the Src-inhibitor, AZD-0530, was 
highly effective in inhibiting dispersion in the absence of 
HUVECs, but this effect was almost completely forfeited 
when HUVECs were added in co-culture. Both of these 
results clearly indicate that other factors secreted by 
endothelial cells also mediate T24 EMT progression 
whereas Src activation is not essential. Since AZD-0530 
is a dual-kinase inhibitor, we also investigated whether 
inhibition of c-abl kinase also leads to the partial inhibition 
of T24 aggregate dispersion, by treating with 10 μM of 
STI-571 (imatinib, data not shown); the results of which 
suggested that c-abl has little or no role in dispersion.
To investigate the role of paracrine signaling by 
HUVECs to T24 cells, individual growth factors were 
examined in the absence of HUVECs and in the presence 
of AZD-0530. Growth factor test results revealed that 
either HGF or FGF-2 can restore aggregate dispersal. In 
this regard, several reports have indicated that HGF/c-
Met pathway activation correlates with bladder cancer 
progression [19–21]. Moreover, muscle invasiveness of 
T24 cells is associated with high levels of HGF in the 
serum and urine [22] [23]. Our study shows that HUVECs 
secrete HGF, which promotes dispersion of T24 cells by 
a mechanism independent of the Src pathway. ELISA and 
neutralizing antibody experiments further validated these 
findings. We also observed that FGF-2 plays a similar 
role to HGF in promoting EMT. FGF-2 is secreted by 
HUVECs and was shown to trigger T24 cell dispersal. 
Previous literature has reported that FGF-2 could lead to 
EMT through Ras-MAPK pathway activation [24, 25]. In 
addition, c-Met and FGFR inhibitor experiments produced 
results that are consistent with our blocking antibody 
observations. The information in this study is proposed 
to be useful to provide a framework to guide the selection 
of the best in class drug combination, to treat invasive 
bladder carcinoma. It is now envisioned to expand this 
study by using tumor biopsies rather cell lines to establish 
new therapeutics regimens.
Our findings regarding Src-mediated T24 aggregate 
dispersion imply that the inhibition of Src kinase might 
partially prevent the collagen-triggered EMT of T24 cell 
aggregates (Figure 6). In type I collagen, β1 integrin is 
the major cellular receptor [26]. As Src kinase transmits 
integrin-dependent signaling, and there is evidence that 
Src is activated at focal adhesions via RhoA, leading to 
enhanced adhesion disassembly in migrating cells [27, 28], 
we suspected that integrin β1 might play a role in Src-
mediated T24 aggregate dispersion. However, blocking 
β1-integrin could not prevent the 3D dispersion of T24 
aggregates. These results differ from those obtained in 
a previous study of individual T24 cell migration [29], 
and suggest that 3D dispersion might rely on different or 
additional mechanisms as compared with migration that 
are perhaps associated with membrane metalloproteases 
[30–32].
MATERIALS AND METHODS
Cell maintenance and preparation of carcinoma 
aggregates
A549 cells transfected with histone H2B-mCherry 
cDNA and T24 urinary bladder carcinoma epithelial 
cells were cultured in DMEM (Gibco/Invitrogen 12100) 
supplemented with 10% FBS (Gibco/Invitrogen). The 
protocol for generating A549-H2B-mCherry stable cells 
is described in the Supplemental Data. HUVECs were 
maintained in microvascular endothelial growth media 
(Lonza EGM-2MV, Basel, Switzerland). The detailed 
method for generating cancer cell aggregates is described 
in our previous study [33, 34].
Microfluidic device design and fabrication
The microfluidic device for this study was fabricated 
from polydimethyl siloxane (PDMS) (Figure 1). The 
PDMS replica is a negative image of the positive relief 
structure of the patterned wafer made by soft lithography. 
A detailed description on fabrication of these tissue culture 
devices can be found elsewhere [35]. The device consists 
of two gel channels flanked by two media channels that 
are formed into closed chambers by bonding a coverslip 
to the PDMS substrate.
The collagen gel solution (2.5 mg/ml, pH = 7.4) was 
first injected into one of gel channels and polymerized 
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at 37°C to form the endothelial cell adhesion channel. 
A HUVEC-containing solution was then injected 
into this channel, and the cells were allowed to form a 
confluent monolayer on the coverslip bottom substrate 
and the gel surface. After 24 h, an aggregate-containing 
collagen gel solution was then pipetted into the second 
gel region to allow gel polymerization via thermal cross-
linking. The average distance between the HUVEC and 
tumor aggregates was < 200 μm, facilitating rapid cell–
cell signaling. Aggregate or individual cell behavior 
was observed via 3D confocal imaging of the gel region 
through the supporting glass coverslip. A detailed 
description of reagent preparation can be found in the 
Supplemental Data.
Characterization of endothelial monolayer
Fluorescent dextran 70-kDa Texas Red (Invitrogen) 
was mixed with culture medium at a concentration of 
12.5 μg/ml. The solution was added to the endothelial 
cell channel, after 24 h of endothelial cell seeding without 
cancer cell aggregates. Using fluorescence microscopy, 
the concentration fields were captured at different time 
points, and their raw intensity profiles were analyzed using 
MATLAB (Mathworks, Boston, MA, USA).
3D drug screening
Four kinase inhibitors regulating EMT on different 
targets (Figure 1(f)) were selected based on our previous 
study with an appropriate range of concentrations using 
A549 and T24 cells, and introduced via the HUVEC 
channel. For each of the two cell lines, mixtures of two of 
the four drugs were combined in identical concentrations 
and tested for drug synergistic rather than additive effects. 
(Every drug stock solution is prepared at 10 mM in 
DMSO. The final DMSO concentration in cell culture 
is < 0.4%). The combination of all four drugs was tested 
on T24 aggregates. 3D image stacks (a range of 100 μm) 
of each individual aggregate were acquired by Fluoview 
1000 confocal microscopy (Olympus, Japan) with a 
20× objective (NA = 0.4). The images were taken at 
0, 12 and 36 h. Dispersion was quantified by Imaris 6.0 
software (Bitplane). Calculation of aggregate dispersion 
is described in Supplemental Data.
Immunofluorescent staining and ELISA
A detailed description of the immunofluorescence 
staining and ELISA can be found in the Supplemental 
Data. The antibodies were VE-cadherin (1:100, mouse; 
Sigma-Aldrich), E-cadherin (1:100, mouse; Sigma-
Aldrich) and vimentin (1:200, mouse; Invitrogen). The 
secondary antibody used was Alexa Fluor 488-conjugated 
anti-mouse IgG antibodies (Invitrogen). Fluorescent 
images were obtained using confocal microscopy. ELISA 
kits were purchased from R&D Systems (HGF: DY294; 
FGF-2: DY233).
Blocking experiments
HGF was blocked with 20 μg/ml anti-HGF (AB-
294-NA, R&D Systems), FGF-2 was blocked with 5 μg/ml 
anti-FGF (AB-233-NA, R&D Systems) and integrin β1 
was blocked with 20 μg/ml anti-integrin β1 (MAB17781, 
R&D Systems), respectively. The blocking antibody was 
added in excess to the experimental setup. In brief, cell 
aggregates were collected from microwells and blocked 
for 4 h before mixing with collagen solution and injecting 
into the microfluidic device. Antibody was continuously 
supplied via cell media in microfluidic channel, and media 
were changed on a twice-daily basis. Aggregate dispersion 
was evaluated at 0 and 36 h.
CONCLUSION
This study employs a microfluidic-based platform, 
integrating quantitative drug screening to interfere with 
mechanisms driving invasion and micro-metastasis 
induced by the cross-talk between invasive cancer cells 
and the microenvironment. We demonstrate the utility of 
this assay in assessing tumor-specific therapeutic potential, 
by determining the efficacy of drugs as single agents 
or in combination; this will be particularly important 
when dealing with highly invasive cancers. The newly 
uncovered therapeutic regimens could then be considered 
for further in vivo investigations. Our laboratory is 
currently testing such drug cocktails in bladder preclinical 
models. In addition, by reproducing EMT in an in vitro 
model using a 3D collagen scaffold with various types of 
cancer cells, we are able to investigate the tumorigenicity 
and invasiveness of organ-specific cancers, with potential 
applications toward the future goal of personalized 
medicine.
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